English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The first pneumococcal conjugate vaccine (PCV7) included 7 serotypes and was licensed for the use in infants and in children 2 years of age, has several problems including an absolute poorer immune response to common serotypes in comparison to PCV13, an hyporesponsiveness to repeated doses, and an uncertain efficacy in risk groups.

Use of 13-valent pneumococcal conjugate vaccine in children older than 5 years of age